期刊
INFLUENZA AND OTHER RESPIRATORY VIRUSES
卷 7, 期 -, 页码 18-23出版社
WILEY
DOI: 10.1111/irv.12176
关键词
Antiviral; influenza; neuraminidase inhibitor; oseltamivir; resistance; zanamivir
资金
- Roche
- GlaxoSmithKline
- Biota on the topic of influenza treatment
Neuraminidase inhibitors (NAIs) are first-line agents for the treatment and prevention of influenza virus infections. As for other antivirals, the development of resistance to NAIs has become an important concern particularly in the case of A(H1N1) viruses and oseltamivir. The most frequently reported change conferring oseltamivir resistance in that viral context is the H275Y neuraminidase mutation (N1 numbering). Recent studies have shown that, in the presence of the appropriate permissive mutations, the H275Y variant can retain virulence and transmissibility in some viral backgrounds. Most oseltamivir-resistant influenza A virus infections can be managed with the use of inhaled or intravenous zanamivir, another NAI. New NAI compounds and non-neuraminidase agents as well as combination therapies are currently in clinical evaluation for the treatment for severe influenza infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据